Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
Breaynazi for Car-T Transplant Medication is a federal award for 249-Network Contract Office 9 (36C249) held by Bristol-Myers Squibb Company. Estimated value $364K ($364K obligated). Current period of performance ends Jun 1, 2027. Last award drew 1 bidder. Place of performance: LAWRENCEVILLE NJ.
Breaynazi for car-t transplant medication
Recompete timing
PublicCurrent PoP ends Jun 1, 2027 (223 days remaining). Agencies typically plan 12–18 months ahead — at 7.3 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 36C24926N0433? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordBristol-Myers Squibb Company — $17.3M obligated across 91 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C24926N0433?
36C24926N0433 (Breaynazi for car-t transplant medication) is a 249-Network Contract Office 9 (36C249) award with a potential value of $364K, currently held by Bristol-Myers Squibb Company. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C249-26-N-0433?
36C249-26-N-0433 is the dashed form of PIID 36C24926N0433 (Breaynazi for car-t transplant medication), held by Bristol-Myers Squibb Company. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C24926N0433?
249-Network Contract Office 9 (36C249) awarded 36C24926N0433 to Bristol-Myers Squibb Company (potential $364K).
Who is the incumbent on 36C24926N0433?
Bristol-Myers Squibb Company is the incumbent with $17.3M across 91 related awards in SCOUT’s public footprint. The current period of performance ends Jun 1, 2027.
When does Bristol-Myers Squibb Company’s 36C24926N0433 come up for recompete?
SCOUT tracks a period-of-performance end of Jun 1, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C24926N0433? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.